Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aldehyde dehydrogenase 6 family member A1 (ALDH6A1) is a mitochondrial enzyme belonging to the aldehyde dehydrogenase family. It catalyzes the irreversible oxidative decarboxylation of malonate and methylmalonate semialdehydes to form acetyl-CoA and propionyl-CoA, essential steps in the catabolism of valine and pyrimidine. Mutations in the ALDH6A1 gene cause a rare metabolic disorder—methylmalonate semialdehyde dehydrogenase deficiency—characterized by accumulation of organic acids in urine and variable neurodevelopmental consequences. Reduced expression of ALDH6A1 is linked to enhanced proliferation in certain cancers, indicating its role in tumorigenesis and its potential as a prognostic biomarker. The enzyme is most highly expressed in the kidney and liver, localized to mitochondria, and contributes to energy and intermediary metabolic regulation.
Enzymatic oxidation (targeted drugs would act by modulating its activity, but there is no evidence of current clinical drugs directly targeting this enzyme)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aldehyde dehydrogenase 6 family member A1 (ALDH6A1).